ARWRArrowhead Pharmaceuticals Inc.
$85.78
$0.25
(0.29%)
Closed $85.78
$1.72
(2.00%)
After Hours
EarningsAug 4
Mkt Cap$12.05B
Vol1.69M
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial...
Business Wire
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia (sHTG), a condition that significantly increases the risk of acute pancreatitis (AP), which is...
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter ended June 30, 2026.Webcast and Conference Call DetailsInvestors may access a live...
Business Wire
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglyceride levels in adult patients with familial...
Business Wire
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the companys proprietary Targeted RNAi Molecule (TRiM) platform. Each webinar in the...
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global Healthcare Conference June 2-4, 2026 Type: Fireside Chat Presentation Date/Time: June 3, 2026, 8:10 am EDT Goldman Sachs 47th Annual Global...
Business Wire
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the companys investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis...
Business Wire
<
1
2
>
Advertisement|Remove ads.
Latest ARWR News
ViewArrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Business Wire
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data
Stocktwits
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval
Stocktwits
MU69
32
DIA35
58
QQQ53
99Advertisement|Remove ads.